Physician profile
Melonie C Proctor
NPI 1205075116
$11,676.37
in general payments reported to CMS, 2019-2025
57 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,423 · 2020: $1,744 · 2021: $2,018 · 2022: $1,788 · 2023: $1,619 · 2024: $1,830 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,684 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.14 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,797.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,136.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $979.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $914.46 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $663.22 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $637.96 | 2019-2025 | |
| Amgen INC. | $550.57 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $365.90 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.83 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $361.19 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $343.92 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $314.90 | 2022-2025 | |
| Allergan, INC. | $276.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.21 | 2019-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $211.93 | 2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melonie Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.